NClip

Psoriatic Drugs

4 min read

Psoriatic Drugs

Key Points

  • Psoriasis treatment commonly combines systemic, topical, and biologic therapies.
  • Systemic options include acitretin and methoxsalen-assisted phototherapy pathways in severe disease.
  • Topical options include calcipotriene, clobetasol, coal tar, and tazarotene.
  • Biologic pathways target inflammatory mediators such as TNF and interleukin pathways.
  • Safety priorities include teratogenic risk, infection risk, UV injury prevention, and adherence to duration/area limits for topical steroids.
  • Baseline and ongoing monitoring should include skin response, infection risk, and renal/hepatic laboratory trends for systemic and biologic pathways.

Systemic Psoriatic Therapy

Systemic treatment is generally reserved for severe or refractory disease.

Common examples:

  • Acitretin (retinoid): often 25-50 mg orally daily with food
  • Methoxsalen: given before UVA exposure (PUVA pathway), not used as monotherapy

Systemic Safety Highlights

  • Retinoid adverse-risk patterns can include hypervitaminosis A toxicity, thromboembolic/cardiovascular events, neuropathy, skin fragility, and severe dermatitis pathways.
  • Contraindications include pregnancy potential/pregnancy/breastfeeding for retinoid pathways.
  • Additional contraindication burden includes significant hepatic, renal, and selected cardiac disease contexts.
  • Methoxsalen plus uncontrolled UV exposure can cause severe burns; strict photoprotection teaching is required.

Topical Psoriatic Therapy

Topical therapies reduce inflammation and plaque burden and are often used with systemic/phototherapy plans.

Common examples:

  • Calcipotriene (vitamin D analog)
  • Clobetasol 0.05% high-potency corticosteroid (typically short course, often up to about 2 weeks; avoid face/genitals/axillae)
  • Coal tar preparations (lotion/shampoo pathways)
  • Tazarotene topical retinoid

Topical Safety Highlights

  • Do not apply to open skin, mucous membranes, or nonapproved body sites.
  • Excessive frequency/amount can worsen redness, flaking, irritation, and skin breakdown.
  • Protect surrounding normal skin when irritating preparations are used on focal plaques.
  • Screen for hypersensitivity and worsening symptoms during therapy.

Biologic Psoriatic Therapy (Overview)

Biologic response modifiers reduce inflammatory signaling in moderate-to-severe psoriasis:

  • TNF-focused pathways: etanercept, infliximab, adalimumab
  • Interleukin-focused pathways: ustekinumab (IL-12/23 pathway)

Biologic Dosing Snapshots (Selected Patterns)

  • Etanercept: 50 mg SC twice weekly for about 3 months, then weekly maintenance (adult pattern; pediatric weight-based variants)
  • Infliximab: 5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks
  • Adalimumab: 80 mg SC initial, then 40 mg every other week
  • Ustekinumab: weight-based SC induction and maintenance every 12 weeks after week-4 dose

Biologic Safety Highlights

  • Hypersensitivity reactions can occur during or after administration.
  • Immunosuppression increases risk for serious infection and secondary malignancy (especially lymphoma risk context).
  • Contraindication context includes active infection and overlapping immunosuppressive burden.
  • TB screening is required before biologic initiation.

Nursing Assessment and Interventions

  • Document baseline skin status and monitor treatment-response trend over time.
  • Monitor adverse effects, contraindication risks, and relevant interaction patterns.
  • Assess psychosocial burden and support coping/adherence plans.
  • Verify required screening completion before restricted systemic therapy is prescribed.
  • Reinforce that application amount/frequency and body-site limits must follow orders exactly.
  • For biologic pathways, monitor for fever/infectious symptoms, hypersensitivity, and long-term malignancy-risk signals.
  • Monitor ordered renal and hepatic labs (for example BUN/creatinine/GFR and liver function tests) during systemic and biologic treatment pathways.

Client Education

  • Take medications exactly as directed and keep all follow-up appointments.
  • Report infection symptoms immediately (for example fever above 100.4 F, chills, productive cough, urinary or yeast-infection symptoms).
  • Avoid pregnancy and breastfeeding when contraindicated by systemic retinoid pathways.
  • Avoid UV exposure during methoxsalen pathways unless specifically protocol-directed.
  • For topical therapy, apply thin layers only to affected plaques, avoid eyes/mucous membranes, and do not use occlusive dressings.
  • Avoid crowd/infection exposure during biologic therapy and avoid close contact with recent live-vaccine recipients.
  • Report worsening redness, excessive dryness/peeling, or persistent irritation.

High-Risk Safety Alerts

Acitretin has severe embryo-fetal toxicity risk. Methoxsalen carries severe photosensitivity and long-term UV injury/cancer risk. Infliximab, adalimumab, and ustekinumab can increase serious infection and secondary malignancy risk.

Graph View